[1]何志伟,胡欣,陈国芳,等.抗氧化剂：治疗甲状腺相关性眼病的新选择[J].眼科新进展,2022,42(5):417-420.[doi:10.13389/j.cnki.rao.2022.0085]
　HE Zhiwei,HU Xin,CHEN Guofang,et al.Antioxidant: a new therapy for thyroid associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(5):417-420.[doi:10.13389/j.cnki.rao.2022.0085]
点击复制

抗氧化剂：治疗甲状腺相关性眼病的新选择/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年5期
页码:
417-420
栏目:
文献综述
出版日期:
2022-05-05

文章信息/Info

Title:
Antioxidant: a new therapy for thyroid associated ophthalmopathy
作者:
何志伟; 胡欣; 陈国芳; 刘超
210028　江苏省南京市，南京中医药大学附属中西医结合医院（何志伟，胡欣，陈国芳，刘超）；210028　江苏省南京市，国家中医药管理局瘿病证治重点研究室（何志伟，陈国芳，刘超）
Author(s):
HE Zhiwei1; 2; HU Xin1; CHEN Guofang1; 2; LIU Chao1; 2
1.Affiliated Hospital of Integrated Traditional Chinese and Western Medicine,Nanjing University of Chinese Medicine,Nanjing 210028,Jiangsu Province,China
2.Key Laboratory of TCM Syndrome & Treatment of Yingbing of State Administration of Traditional Chinese Medicine,Nanjing 210028,Jiangsu Province,China
关键词:
甲状腺相关性眼病; 抗氧化剂; 氧化应激; 活性氧; 硒
Keywords:
thyroid associated ophthalmopathy;  antioxidant;  oxidative stress;  reactive oxygen species;  selenium
分类号:
R771.3
DOI:
10.13389/j.cnki.rao.2022.0085
文献标志码:
A
摘要:
甲状腺相关性眼病（TAO）是一种器官特异性自身免疫性疾病，其发病机制复杂，可引起一系列眼部症状，对患者的生活质量和心理健康造成严重影响。目前针对TAO的各种治疗方式均不尽如人意。鉴于氧化应激与TAO的发病密切相关，且硒作为抗氧化剂可有效改善轻度TAO患者的临床症状和生活质量，故抗氧化治疗成为处理TAO的新选择。体外研究显示，维生素C、N-乙酰-L-半胱氨酸、β-胡萝卜素等抗氧化剂可以减少TAO患者眼眶炎症因子的释放，并抑制成纤维细胞的增殖。此外，一些中药活性成分，如槲皮素、虎杖苷、甲基莲心碱具有抗氧化作用，同样能抑制眼眶成纤维细胞的增殖，提示这些药物或制剂或许可以应用于TAO的临床治疗。
Abstract:
Thyroid associated ophthalmopathy (TAO) is an organ-specific autoimmune disease with a complex pathogenesis, which can cause a series of ocular symptoms and seriously affect the quality of life and mental health of patients. The various treatments currently available for TAO are unsatisfactory. Given that oxidative stress is closely associated with the development of TAO and that selenium, as an antioxidant, can effectively improve the clinical symptoms and quality of life of patients with mild TAO, antioxidant therapy is a new option for the treatment of TAO. In vitro studies have shown that antioxidants such as vitamin C, N-acetyl-L-cysteine, and β-carotene can reduce the release of orbital inflammatory cytokines and inhibit the proliferation of fibroblasts in patients with TAO. In addition, some active ingredients of Chinese herbs, such as quercetin, polydatin and neferine, have antioxidant effects and can also inhibit the proliferation of orbital fibroblasts, suggesting that these drugs or preparations may be applied in the clinical treatment of TAO.

参考文献/References:

［1］　BARTALENA L,PIANTANIDA E,GALLO D,LAI A,TANDA M L.Epidemiology,natural history,risk factors,and prevention of Graves’ orbitopathy［J］.Front Endocrinol (Lausanne),2020,11:615993.
［2］　BRUSCOLINI A,SACCHETTI M,LA CAVA M,NEBBIOSO M,IANNITELLI A,QUARTINI A,et al.Quality of life and neuropsychiatric disorders in patients with Graves’ orbitopathy:current concepts［J］.Autoimmun Rev,2018,17(7):639-643.
［3］　SMITH T J,BARTALENA L.Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy?［J］.Eur J Endocrinol,2019,181(5):D27-D43.
［4］　LANZOLLA G,MARCOCCI C,MARIN M.Oxidative stress in Graves disease and Graves orbitopathy［J］.Eur Thyroid J,2020,9(Suppl 1):40-50.
［5］　GONTARZ-NOWAK K,SZYCHLI N＇SKA M,MATUSZEWSKI W,STEFANOWICZ-RUTKOWSKA M,BANDURSKA-STANKIEWICZ E.Current knowledge on Graves’ orbitopathy［J］.J Clin Med,2020,10(1):16-38.
［6］　SMITH T J.TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy［J］.Nat Rev Endocrinol,2015,11(3):171-181.
［7］　SMITH T J.The insulin-like growth factor-I receptor and its role in thyroid-associated ophthalmopathy［J］.Eye (Lond),2019,33(2):200-205.
［8］　VALKO M,LEIBFRITZ D,MONCOL J,CRONIN M T,MAZUR M,TELSER J.Free radicals and antioxidants in normal physiological functions and human disease［J］.Int J Biochem Cell Biol,2007,39(1):44-84.
［9］　TSAI C C,WU S B,CHENG C Y,KAO S C,KAU H C,LEE S M,et al.Increased response to oxidative stress challenge in Graves’ ophthalmopathy orbital fibroblasts［J］.Mol Vis,2011,17:2782-2788.
［10］　TSAI C C,WU S B,CHENG C Y,KAO S C,KAU H C,ChIOU S H,et al.Increased oxidative DNA damage,lipid peroxidation,and reactive oxygen species in cultured orbital fibroblasts from patients with Graves’ophthalmopathy:evidence that oxidative stress has a role in this disorder［J］.Eye (Lond),2010,24(9):1520-1525.
［11］　DIANA T,DAIBER A,OELZE M,NEUMANN S,OLIVO P D,KANITZ M,et al.Stimulatory TSH-receptor antibodies and oxidative stress in graves disease［J］.J Clin Endocrinol Metab,2018,103(10):3668-3677.
［12］　GRTZ G E,HORSTMANN M,ANIOL B,REYES B D,FANDREY J,ECKSTEIN A,et al.Hypoxia-dependent HIF-1 activation impacts on tissue remodeling in Graves’ ophthalmopathy-implications for smoking［J］.J Clin Endocrinol Metab,2016,101(12):4834-4842.
［13］　BARTALENA L,TANDA M L,PIANTANIDA E,LAI A.Oxidative stress and Graves’ ophthalmopathy:in vitro studies and therapeutic implications［J］.Biofactors,2003,19(3/4):155-163.
［14］　HEUFELDER A E,WENZEL B E,BAHN R S.Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’ retroocular fibroblasts［J］.J Clin Endocrinol Metab,1992,74(4):737-742.
［15］　BURCH H B,LAHIRI S,BAHN R S,BARNES S.Superoxide radical production stimulates retroocular fibroblast proliferation in Graves’ ophthalmopathy［J］.Exp Eye Res,1997,65(2):311-316.
［16］　HONDUR A,KONUK O,DINCEL A S,BILGIHAN A,UNAL M,HASANREISOGLU B.Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves’ ophthalmopathy［J］.Curr Eye Res,2008,33(5):421-427.
［17］　WIERSINGA W M.Smoking and thyroid［J］.Clin Endocrinol (Oxf),2013,79(2):145-151.
［18］　KAU H C,WU S B,TSAI C C,LIU C J,WEI Y H.Cigarette smoke extract-induced oxidative stress and fibrosis-related genes expression in orbital fibroblasts from patients with Graves’ ophthalmopathy［J］.Oxid Med Cell Longev,2016,2016:4676289.
［19］　WINTHER K H,RAYMAN M P,BONNEMA S J,HEGEDS L.Selenium in thyroid disorders - essential knowledge for clinicians［J］.Nat Rev Endocrinol,2020,16(3):165-176.
［20］　DRUTEL A,ARCHAMBEAUD F,CARON P.Selenium and the thyroid gland:more good news for clinicians［J］.Clin Endocrinol (Oxf),2013,78(2):155-164.
［21］　MARIN M,DOTTORE G R,LEO M,MARCOCCI C.Mechanistic pathways of selenium in the treatment of Graves’ disease and Graves’ orbitopathy［J］.Horm Metab Res,2018,50(12):887-893.
［22］　MARCOCCI C,KAHALY G J,KRASSAS G E,BARTALENA L,PRUMMEL M,STAHL M,et al.Selenium and the course of mild Graves’ orbitopathy［J］.N Engl J Med,2011,364(20):1920-1931.
［23］　ROTONDO D G,LEO M,CASINI G,LATROFA F,CESTARI L,SELLARI-FRANCESCHINI S,et al.Antioxidant actions of Selenium in orbital fibroblasts:a basis for the effects of selenium in Graves’ orbitopathy［J］.Thyroid,2017,27(2):271-278.
［24］　ROTONDO D G,CHIARINI R,DE GREGORIO M,LEO M,CASINI G,CESTARI L,et al.Selenium rescues orbital fibroblasts from cell death induced by hydrogen peroxide:another molecular basis for the effects of selenium in Graves’ orbitopathy［J］.Endocrine,2017,58(2):386-389.
［25］　MENCONI F,PROFILO M A,LEO M,SISTI E,ALTEA M A,ROCCHI R,et al.Spontaneous improvement of untreated mild Graves’ ophthalmopathy:rundle’s curve revisited［J］.Thyroid,2014,24(1):60-66.
［26］　BARTALENA L,KAHALY G J,BALDESCHI L,DAYAN C M,ECKSTEIN A,MARCOCCI C,et al.The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy［J］.Eur J Endocrinol,2021,185(4):43-67.
［27］　ROTONDO D G,IONNI I,MENCONI F,CASINI G,SELLARI-FRANCESCHINI S,NARDI M,et al.Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO):a new frontier for GO treatment?［J］.J Endocrinol Invest,2018,41(2):193-201.
［28］　BALAZS C,KISS E,VAMOS A,MOLNAR I,FARID N R.Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (Tao):a pilot study［J］.J Clin Endocrinol Metab,1997,82(6):1999-2002.
［29］　ROTONDO D G,IONNI I,MENCONI F,CASINI G,SELLARI-FRANCESCHINI S,NARDI M,et al.Antioxidant effects of β-carotene,but not of retinol and vitamin E,in orbital fibroblasts from patients with Graves’ orbitopathy (GO)［J］.J Endocrinol Invest,2018,41(7):815-820.
［30］　LISI S,BOTTA R,LEMMI M,SELLARI-FRANCESCHINI S,ALTEA M A,SISTI E,et al.Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid［J］.J Endocrinol Invest,2011,34(7):521-527.
［31］　LI H,MIN J,CHEN Y,LI H,ZHANG Y.Polydatin attenuates orbital oxidative stress in Graves’ orbitopathy through the NRF2 pathway［J］.Chem Biol Interact,2020,315:108894.
［32］　POORNIMA P,WENG C F,PADMA V V.Neferine from nelumbo nucifera induces autophagy through the inhibition of PI3K/Akt/mTOR pathway and ROS hyper generation in A549 cells［J］.Food Chem,2013,141(4):3598-3605.
［33］　LI H,GAO L,MIN J,YANG Y,ZHANG R.Neferine suppresses autophagy-induced inflammation,oxidative stress and adipocyte differentiation in Graves’ orbitopathy［J］.J Cell Mol Med,2021,25(4):1949-1957.
［34］　BOTTA R,LISI S,MARCOCCI C,SELLARI-FRANCESCHINI S,ROCCHI R,LATROFA F,et al.Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts［J］.Thyroid,2013,23(1):92-96.

相似文献/References:

[1]杨忠昆 朱勤 胡竹林.改良三壁眶减压术治疗重症甲状腺相关性眼病的疗效观察[J].眼科新进展,2012,32(9):000.
[2]陆燕,黄媛媛,蔡季平,等. SB431542和TGF-β1对甲状腺相关性眼病患者眼眶成纤维细胞α-SMA及CTGF基因表达的影响[J].眼科新进展,2015,35(3):210.[doi:10.13389/j.cnki.rao.2015.0057]
　LU Yan,HUANG Yuan-Yuan,CAl Ji-Ping,et al. Effects of SB431542 and TGF-B1 0n a-SMA and CTGF gene expression in orbital fibroblast of patients with thyroid-associated ophthalmolopathy[J].Recent Advances in Ophthalmology,2015,35(5):210.[doi:10.13389/j.cnki.rao.2015.0057]
[3]曹秀朋,陈霞,郭雅图,等.枸杞子提取物对光诱导视网膜损伤的保护作用[J].眼科新进展,2020,40(6):510.[doi:10.13389/j.cnki.rao.2020.0117]
　CAO Xiupeng,CHEN Xia,GUO Yatu,et al.Protective effect of wolfberry extract on light-induced retinal damage[J].Recent Advances in Ophthalmology,2020,40(5):510.[doi:10.13389/j.cnki.rao.2020.0117]
[4]陈若瑜,曹丹,张良.糖尿病视网膜病变药物治疗研究进展[J].眼科新进展,2022,42(3):244.[doi:10.13389/j.cnki.rao.2022.0050]
　CHEN Ruoyu,CAO Dan,ZHANG Liang.Advances in drug therapy for diabetic retinopathy[J].Recent Advances in Ophthalmology,2022,42(5):244.[doi:10.13389/j.cnki.rao.2022.0050]
[5]万光明,薛瑢.从视网膜氧化应激与微血管改变谈糖尿病视网膜病变的发病机制和防治策略[J].眼科新进展,2022,42(7):505.[doi:10.13389/j.cnki.rao.2022.0103]
　WAN Guangming,XUE Rong.Discussion on the pathogenesis and prevention of diabetic retinopathy from retinal oxidative stress and microvascular changes[J].Recent Advances in Ophthalmology,2022,42(5):505.[doi:10.13389/j.cnki.rao.2022.0103]
[6]张浩,赵婧,葛小宁,等.甲状腺相关性眼病的诊断性生物标志物研究进展[J].眼科新进展,2022,42(7):562.[doi:10.13389/j.cnki.rao.2022.0115]
　ZHANG Hao,ZHAO Jing,GE Xiaoning,et al.Research progress in diagnostic biomarkers for thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2022,42(5):562.[doi:10.13389/j.cnki.rao.2022.0115]
[7]王星,张岩岩,王利圆,等.潜在抗氧化剂在年龄相关性黄斑变性中应用的研究进展[J].眼科新进展,2022,42(12):989.[doi:10.13389/j.cnki.rao.2022.0203]
　WANG Xing,ZHANG Yanyan,WANG Liyuan,et al.Research progress of the application of potential antioxidants in age-related macular degeneration[J].Recent Advances in Ophthalmology,2022,42(5):989.[doi:10.13389/j.cnki.rao.2022.0203]
[8]孔雪晴,沙咏怡,项敏泓.氧化应激及天然食物中的抗氧化剂在干眼中的作用研究进展[J].眼科新进展,2024,44(3):235.[doi:10.13389/j.cnki.rao.2024.0046]
　KONG Xueqing,SHA Yongyi,XIANG Minhong.Research progress on oxidative stress and effects of antioxidants from natural foods on dry eyes[J].Recent Advances in Ophthalmology,2024,44(5):235.[doi:10.13389/j.cnki.rao.2024.0046]
[9]张皙苒,张馨心,康志明,等.甲状腺相关性眼病患者眼表及肠道菌群的研究进展[J].眼科新进展,2024,44(6):494.[doi:10.13389/j.cnki.rao.2024.0095]
　ZHANG Xiran,ZHANG Xinxin,KANG Zhiming,et al.Advances in ocular surface and intestinal flora of patients with thyroid-associated ophthalmopathy[J].Recent Advances in Ophthalmology,2024,44(5):494.[doi:10.13389/j.cnki.rao.2024.0095]

备注/Memo

备注/Memo:
第二批江苏省中医药领军人才项目（编号：SLJ0209）
更新日期/Last Update: 2022-05-22